Summary

President-elect Donald Trump’s nominee to lead the Centers for Medicare & Medicaid Services (CMS), Dr. Mehmet Oz, faces scrutiny over significant financial investments in health care, pharmaceutical, and food industries—sectors regulated by CMS.

His holdings, disclosed during a 2022 Senate campaign, include stakes in UnitedHealth, CVS, and pharmaceutical companies, raising conflict-of-interest concerns.

While Oz has not confirmed if he will divest these assets, critics question his ability to act impartially.

Proponents cite his Medicare Advantage support, but critics warn his proposals could increase taxes.

Oz’s mixed reception highlights concerns about ethics and policy expertise.